Video

El Rol de Los Tripletes en el Tratamiento de la Leucemia Aguda Mieloblástica

Nidia Zapata, MD, discusses the role of triplet therapy in the treatment of patients with acute myeloid leukemia.

Nidia Zapata, MD, associate professor, Instituto Nacional de Cancerologia, discusses the role of triplet therapy in the treatment of patients with acute myeloid leukemia (AML).

Zapata: The use of triplet combinations is an excellent investigational question that is generating a lot of anticipation, regarding the results that are expected within the space of patients with AML who are not suitable candidates for intensive therapy.

The results [of triplet therapy] have shown significant toxicity, but many of the current approaches focus on adjusting dosing strategies or making changes in the dosing of treatment to make these combinations more tolerable and less toxic for patients. These combinations [are] an excellent [approach], and I believe there is a lot of anticipation for results that will [be read out] at upcoming [medical meetings] to [let us] see these outcomes.

Editor's Note: Dr Zapata's transcript has been translated from Spanish to English.

Related Videos
Tanios Bekaii-Saab, MD, FACP
Moritz Fürstenau, MD
Jun Gong, MD
Thierry Facon, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Marshall Posner, MD
Renee Saliby, MD, MSc
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS